NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a student of Buffett and Graham, I start with the business, not the story. NewAmsterdam Pharma is a late-stage biopharmaceutical company with about 100 employees, developing obicetrapib, an oral CETP inhibitor, for cardiometabolic disease and in a Phase 2a Alzheimer's trial. That is a promising scientific bet, but it is not yet a proven business. In fiscal 2023, it reported revenue of $14.1M and a net loss of $176.9M, or diluted EPS of -$2.15. In fiscal 2024, revenue rose to $45.6M while net loss was $241.6M, or -$2.56 per diluted share. In fiscal 2025, revenue fell to $22.5M and net loss was $203.8M, or -$1.72. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was just $3.7M and net loss was $64.1M, or -$0.52 per diluted share. Trailing free cash flow is -$143.7M, so cash is consumed, not produced. FairStock calculations show a P/E of -9.35, P/B of 3.76, ROE of -36.81%, ROCE of -20.11%, and Piotroski F-Score of 2/9. D/E is 0.00 and Altman Z-Score is 18.79, which suggest little debt and no near-term balance-sheet distress by those measures, but the company still depends on external capital. At $20.19 on 2026-10-13, market cap is $2.4B against negligible revenue and no profits. Graham would demand a margin of safety; here, the price rests almost entirely on pipeline hope. The supplied Lynch category is none, because it has lost money in each of the last four years. Without an approved product described in the data, I see no durable competitive moat, only the possibility of one if obicetrapib wins in late-stage trials. This is a speculative clinical story, not a Graham-style value investment.

In plain English: NewAmsterdam Pharma is a healthcare company trying to develop an oral cholesterol-lowering medicine and an Alzheimer's treatment. It has not made a profit in the last four years, its revenue is very small, and it is spending more cash than it brings in, so the business looks financially weak today. At $20.19 on 2026-10-13, the $2.4B price looks expensive compared with current sales and losses, though the value depends on whether its experimental drugs succeed.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer